Skip to Main Content

++

  1. Pharmacology. Esmolol is a short-acting, IV, cardioselective beta-adrenergic blocker with no intrinsic sympathomimetic or membrane-depressant activity. In usual therapeutic doses, it causes little or no bronchospasm in patients with asthma. Esmolol produces peak effects within 6–10 minutes of administration of an intravenous bolus. It is hydrolyzed rapidly by red blood cell esterases, with an elimination half-life of 9 minutes; therapeutic and adverse effects disappear within 30 minutes after the infusion is discontinued.

  2. Indications

    1. Rapid control of supraventricular and ventricular tachyarrhythmias and hypertension, especially if caused by excessive sympathomimetic activity (eg, stimulant drugs, hyperthyroid state).

    2. Reversal of hypotension and tachycardia caused by excessive beta-adrenergic activity resulting from theophylline or caffeine overdose.

    3. Control of ventricular tachyarrhythmias caused by excessive myocardial catecholamine sensitivity (eg, chloral hydrate and chlorinated hydrocarbon solvents).

  3. Contraindications

    1. Contraindications include hypotension, bradycardia, and congestive heart failure secondary to intrinsic cardiac disease or cardiac-depressant effects of drugs and toxins (eg, cyclic antidepressants and barbiturates).

    2. Hypertension caused by alpha-adrenergic or generalized stimulant drugs (eg, cocaine, amphetamines), unless esmolol is co-administered with a vasodilator (eg, nitroprusside or phentolamine). Paradoxic hypertension may result from an unopposed alpha effect, although it is less likely than that associated with the use of a nonspecific beta-adrenergic blocker (propranolol).

  4. Adverse effects

    1. Hypotension and bradycardia may occur, especially in patients with intrinsic cardiac disease or cardiac-depressant drug overdose.

    2. Bronchospasm may occur in patients with asthma or chronic bronchospasm, but it is less likely than with propranolol or other nonselective beta blockers and is rapidly reversible after the infusion is discontinued.

    3. Esmolol may mask physiologic responses to hypoglycemia (tremor, tachycardia, and glycogenolysis) and therefore should be used with caution in patients with diabetes.

    4. Use in pregnancy. FDA Category C (indeterminate). This does not preclude its short-term use for a seriously symptomatic patient (See Introduction in Section III). High-dose infusion may contribute to placental ischemia.

  5. Drug or laboratory interactions

    1. Esmolol may transiently increase the serum digoxin level by 10–20%, but the clinical significance of this is unknown.

    2. Recovery from succinylcholine-induced neuromuscular blockade may be delayed slightly (5–10 minutes). Similarly, esmolol metabolism may be inhibited by anticholinesterase agents (eg, organophosphates).

    3. Esmolol is not compatible with sodium bicarbonate solutions.

  6. Dosage and method of administration

    1. Dilute before intravenous injection to a final concentration of 10 mg/mL with 5% dextrose, lactated Ringer's injection, or saline solutions.

    2. Give as an intravenous infusion, starting at 0.025–0.05 mg/kg/min and increasing as needed up to 0.2 mg/kg/min (average dose, 0.1 mg/kg/min). Steady-state concentrations are reached approximately 30 minutes after each infusion adjustment. A loading dose of 0.5 mg/kg should be given over 1 minute if more rapid onset of clinical effects (5–10 minutes) is desired.

    3. Infusion rates greater than 0.2 mg/kg/min are likely to produce excessive hypotension. At rates greater than 0.3 mg/kg/min, the beta-blocking effects lose their beta1 selectivity.

  7. Formulations

    1. Parenteral. Esmolol hydrochloride (Brevibloc), 2.5 g in 10-mL ampules (250 mg/mL), 100 mg in 10-mL vials (10 mg/mL), and 20 mg/mL (double strength) in 5-mL vials and 100-mL bags.

    2. Suggested minimum stocking levels to ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.